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Inducible Deletion of Protein Kinase Map4k4 in Obese Mice Improves
Insulin Sensitivity in Liver and Adipose Tissues
Laura V. Danai,a Rachel J. Roth Flach,a Joseph V. Virbasius,a Lorena Garcia Menendez,a* Dae Young Jung,a Jong Hun Kim,a
Jason K. Kim,a,b Michael P. Czecha
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USAa; Department of Medicine, Division of Endocrinology,
Metabolism and Diabetes, University of Massachusetts Medical School, Worcester, Massachusetts, USAb
Studies in vitro suggest that mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) attenuates insulin signaling, but
confirmation in vivo is lacking since Map4k4 knockout is lethal during embryogenesis. We thus generated mice with floxed
Map4k4 alleles and a tamoxifen-inducible Cre/ERT2 recombinase under the control of the ubiquitin C promoter to induce
whole-bodyMap4k4 deletion after these animals reachedmaturity. Tamoxifen administration to these mice inducedMap4k4
deletion in all tissues examined, causing decreased fasting blood glucose concentrations and enhanced insulin signaling to AKT
in adipose tissue and liver but not in skeletal muscle. Surprisingly, however, mice generated with a conditional Map4k4 deletion
in adiponectin-positive adipocytes or in albumin-positive hepatocytes displayed no detectable metabolic phenotypes. Instead,
mice withMap4k4 deleted inMyf5-positive tissues, including all skeletal muscles tested, were protected from obesity-induced
glucose intolerance and insulin resistance. Remarkably, these mice also showed increased insulin sensitivity in adipose tissue but
not skeletal muscle, similar to the metabolic phenotypes observed in inducible whole-body knockout mice. Taken together, these
results indicate that (i) Map4k4 controls a pathway inMyf5-positive cells that suppresses whole-body insulin sensitivity and (ii)
Map4k4 is a potential therapeutic target for improving glucose tolerance and insulin sensitivity in type 2 diabetes.
Whole-body glucose homeostasis in humans is maintained byan elaborate physiological system that involves multiorgan
regulation. In the postprandial state, glucose and amino acids in-
duce  cells in the pancreas to secrete insulin, promoting glucose
uptake in skeletal muscle and adipose tissue while suppressing
glucose production from the liver. These effects of insulin to
maintain glucose homeostasis can be disrupted in obesity, causing
an insulin-resistant state that contributes to elevated blood glu-
cose levels and an increased incidence of type 2 diabetes (T2D) (1).
While metformin (thought to mainly affect liver glucose metabo-
lism) and insulin secretagogues are clinicalmainstays for the treat-
ment of T2D, further intervention is often required (2). Due to
contraindications, treatments that address the underlying periph-
eral insulin resistance in T2D are now limited to the use of the
thiazolidinediones (TZDs), amajor drug class that alleviates insu-
lin resistance by targeting peroxisome proliferator-activated re-
ceptor gamma (PPAR) (3, 4). Thus, novel proteins that could be
targeted with drugs to enhance peripheral insulin sensitivity
would prove useful in developing therapies for T2D.
In screening the adipocyte kinome for such negative regulators
of insulin signaling to glucose transport in vitro, we identified
mitogen-activated protein kinase kinase kinase kinase 4
(Map4k4), a serine/threonine protein kinase with homology to
Saccharomyces cerevisiae Ste20 protein kinases (5). Interestingly,
single nucleotide polymorphisms (SNPs) in theMap4k4 locus ap-
pear to be associated with insulin resistance (6) and T2D (7). We
therefore hypothesized that Map4k4 may be a novel therapeutic
target for improving obesity-induced peripheral insulin resis-
tance. The functions of Map4k4 in insulin signaling and energy
metabolism were subsequently studied in various cell culture
models. In adipocytes, Map4k4 repressed glucose transport and
lipid synthesis (5, 8), while in human myotubes, Map4k4 deple-
tion protected cells from tumor necrosis factor alpha (TNF-)-
induced insulin resistance (9). These studies suggested that sys-
temic Map4k4 depletion might improve whole-body glucose
metabolism in obesity. However, the effects of systemic Map4k4
deficiency on metabolic disease in vivo have not yet been studied
due to the embryonic lethality of Map4k4-null mice (10). To cir-
cumvent this problem, we generated an inducible gene deletion
mouse model to investigate the physiological effects of Map4k4
depletion that appear once mice reach maturity. We sought to
address several questions employing this model. First, is Map4k4
required for viability of adult mice? Second, is Map4k4 a negative
regulator of systemic insulin sensitivity andmetabolic function in
obese animals? Last, in what tissue or tissues might Map4k4 oper-
ate to modulate whole-body glucose homeostasis and insulin re-
sponsiveness?
Here we report that mature mice with induced systemic
Map4k4 ablation (iMap4k4 knockout [iMap4k4-KO] mice) are
viable and, when challenged with high-fat feeding, display lower
fasting glucose levels and improved peripheral insulin sensitivity.
By generatingmultiple tissue-specificMap4k4 knockoutmice, we
found thatMap4k4 deficiency in cells fromaMyf5 lineage, includ-
ing skeletal muscles, but not selective Map4k4 deficiency in adi-
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pose cells or hepatocytes recapitulates the improved systemic in-
sulin sensitivity observed in whole-body iMap4k4-KO mice.
MATERIALS AND METHODS
Animal studies. All of the studies performed were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of the University of
Massachusetts (UMass) Medical School. Animals were maintained under
conditions of a 12-h-light/12-h-dark cycle and fed standard chow (Lab-
Diet 5P76) unless otherwise stated. Mice with conditional Map4k4 floxed
alleles were generated as described elsewhere (11) andwere backcrossed to
C57BL/6J mice for at least 7 generations. To inactivate Map4k4 in adult
mice, homozygous Map4k4flox/flox animals were crossed to B6.Cg-
Tg(UBC-cre/ERT2)1Ejb/J mice (Jackson Laboratories). Mice (both
Map4k4flox/flox and Map4k4flox/flox-UBC-cre ERT2) that were 8 weeks of
age were treated via intraperitoneal (i.p.) injection with 30 g tamoxifen
(dissolved in corn oil)/40 g body weight for 5 consecutive days. At 2 weeks
after first tamoxifen injection, animals were fed a normal chow diet (ND)
or a high-fat diet (HFD) (12492i; Harlan) for 16 weeks.
Adiponectin-cre mice [B6; FVB-Tg(Adipoq-cre)1Evdr/J], albumin-
cremice [C57BL/6-Tg(Alb-cre)21Mgn/J], andMyf-5 cremice [B6.129S4-
Myf5tm3(cre)Sor/J] were obtained from Jackson Laboratories.
Mice were fasted for 16 h for a glucose tolerance test (GTT) and a
pyruvate tolerance test (PTT) or for 4 h for an insulin tolerance test (ITT).
Fasted mice were i.p. injected with glucose (1 g/kg), pyruvate (1 g/kg), or
insulin (1 IU/kg). Blood samples were withdrawn via the tail vein, and
blood glucose levels were determined using a Breeze-2 glucose meter
(Bayer).
Metabolic cage and body composition analyses were performed by
personnel at the UMass Mouse Metabolic Phenotyping Center. The met-
abolic cages were used to measure food and water intake over a 3-day
period, and average food intake/day was calculated (TSE Systems).
Whole-body fat and lean mass were measured using proton magnetic
resonance spectroscopy (1H-MRS) (Echo Medical System).
RNA isolation and RT-qPCR. Total RNAwas isolated from tissues us-
ingTriPure isolation reagent (Roche) following themanufacturer’s protocol.
Isolated RNA was DNase treated (DNA-free; Life Technologies), and cDNA
was synthesized using an iScript cDNA synthesis kit (Bio-Rad). Reverse tran-
scription-quantitative PCR (RT-qPCR) was performed using iQ Sybr green
supermix, and 36B4 (Rplp0) served as the reference gene. Primer sequences
were as follows: for Rplp0, 5=-TCCAGGCTTTGGGCATCA-3= and 3=-CTT
TATCAGCTGCACATCACTCAGA-5=; forMap4k4, 5=-CATCTCCAGGGA
AATCCTCAGG-3= and 3=-TTCTGTAGTCGTAAGTGGCGTCTG-5=; for
Emr-1, 5=-CCCCAGTGTCCTTACAGAGTG-3= and 3=-GTGCCCAGAGT
GGATGTCT-5=; for CD68, 5=-CCATCCTTCACGATGACACCT-3= and 3=-
GGCAGGGTTATGAGTGACAGTT-5=; for Itgam, 5=-ATGGACGCTGATG
GCAATACC-3= and 3=-TCCCCATTCACGTCTCCCA-5=; for Itgax, 5=-CT
GGATAGCCTTTCTTCTGCTG-3= and 3=-GCACACTGTGTCCGAACTC
A-5=; for interleukin-1  (IL-1), 5=-GCAACTGTTCCTGAACTCAACT-3=
and 3=-ATCTTTTGGGGTCCGTCAACT-5=; for CCL2, 5=-TTAAAAACCT
GGATCGGAACCAA-3= and 3=-GCATTAGCTTCAGATTTACGGGT-5=;
for TNF-, 5=-CAGGCGGTGCCTATGTCTC-3= and 3=-CGATCACCCCG
AAGTTCAGTAG-5=; for Pepck, 5=-CTGCATAACGGTCTGGACTTC-3=
and 3=-CAGCAACTGCCCGTACTCC-5=; for G6pc, 5=-CGACTCGCTATC
TCCAAGTGA-3= and 3=-GTTGAACCAGTCTCCGACCA-5=; for Gck, 5=-T
GAGCCGGATGCAGAAGGA-3= and 3=-GCAACATCTTTACACTGGCC
T-5=; for Fasn, 5=-GGAGGTGGTGATAGCCGGTAT-3= and 3=-TGGGTAA
TCCATAGAGCCCAG-5=; and for Scd-1, 5=-TTCTTGCGATACACTCTGG
TGC-3= and 3=-CGGGATTGAATGTTCTTGTCGT-5=.
Plasma analysis. Mice were fasted overnight, and plasma was col-
lected via cardiac puncture. Serum nonesterified fatty acid (NEFA) levels
were measured using a colorimetric assay (Wako Diagnostics) according
to the manufacturer’s instructions. Alternatively, animals were injected
with 0.5 mg/kg CL 316,243 (Santa Cruz) dissolved in phosphate-buffered
saline (PBS) and blood was collected via tail vein after 1 h. Insulin mea-
surements were performed using an insulin enzyme-linked immunosor-
bent assay (ELISA) kit (Millipore) according to the manufacturer’s in-
structions.
Histology. Tissues were isolated and fixed in 10% formalin, embed-
ded in paraffin, sectioned, and stained with hematoxylin and eosin
(H&E). The UMass Morphology Core performed the embedding and
sectioning.
Adipocyte isolation. Adipose tissue was minced in digestion buffer
(5% bovine serum albumin [BSA]–1 mg/ml collagenase [Sigma no.
C6885]–Hanks balanced salt solution [HBSS]) and digested in a 37°C
water bath for 30 to 45 min. Digested tissue was filtered through a 200-
m-pore-size nylonmesh and centrifuged at a low speed for 5min. Float-
ing adipocytes were washed several times in HBSS followed by centrifu-
gation.
Hepatocyte isolation. Hepatocytes were isolated as previously de-
scribed (12). Briefly, chow-fed animals were anesthetized via i.p. ket-
amine-xylazine injection. Livers were perfused and then digested with 50
mg/ml collagenase (Sigma no. C2139) in HBSS that had been supple-
mentedwith 0.5MEGTA and 1mMCaCl2. Digested livers were collected,
filtered through a 100-m-pore-size cell strainer, and centrifuged and
washed several times at a low speed.
Immunoblotting. For in vivo insulin signaling studies, mice were
fasted for 4 h and injected with PBS or insulin (1 IU/kg). At 15 min after
the injection, tissues were rapidly harvested. Tissues were homogenized in
lysis buffer (20 mM HEPES [pH 7.4], 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100, 0.1% SDS, 10% glycerol, 0.5% sodium deoxycholate) that
had been supplemented with Halt protease and phosphatase inhibitors
(Thermo Pierce). For Map4k4 expression analysis, tissues were homoge-
nized in lysis buffer containing 150 mMNaCl, 2 mM EDTA, and 2% SDS
supplemented with protease and phosphatase inhibitors. Immunoblot-
ting was performed using standard protocols. Membranes were blotted
with the following antibodies: AKT (T308, no. 2965; S473, no. 3787; total,
no. 2920; Cell Signaling Technology) and Map4k4 (no. A301-503A;
Bethyl Laboratories).
TG extraction. Livers were isolated fromHFD-fed animals and frozen
in liquid nitrogen. Hepatic triglycerides (TGs) were extracted using the
method of Folch et al. (13). Evaporated lipids with resuspended in 1%
Triton X-100 dissolved in isopropanol. TG content was determined using
the protocol of the manufacturer (triglyceride determination kit; Sigma).
Flow cytometry. The stromal vascular fraction (SVF) of the visceral
adipose tissue (VAT) was isolated and weighed, and subsequent flow cy-
tometry was performed as previously described (14). Briefly, VAT was
minced in digestion buffer (5% BSA–2 mg/ml collagenase–HBSS) and
incubated in a 37°C water bath for 45 min. The digested tissue was passed
through a 100-m-pore-size cell strainer and centrifuged. The pelleted
cells were collected as the SVF, and red blood cells were lysed by incuba-
tion with red blood cell lysis buffer. SVF cells were blocked in mouse IgG
and counted. The antibodies used included F4/80 (antigen-presenting
cells [APC]; AbDSerotec), CD11b (PerCP-Cy 5.5; BD), and CD11c
(V450; BD).
Statistics. Results are described as the means standard errors of the
means (SEM). Significancewas assessed using a two-tailed Student’s t test.
RESULTS
iMap4k4-KO mice display low fasting blood glucose levels and
improved insulin responsiveness. To investigate the functional
role of Map4k4 in whole-body glucose homeostasis, we deleted
Map4k4 systemically. However, whole-body Map4k4-KO ani-
mals die at embryonic day 9.5 (E9.5) due to failure of mesoder-
mal cells to migrate away from the primitive streak (10). To
bypass the necessary role of Map4k4 during embryonic devel-
opment (10), we generated Map4k4 floxed mice (bearing loxP
sites around exon 7) with tamoxifen-inducible UBC-cre ERT2
recombinase to inducibly delete Map4k4 in adult mice (Fig.
1A). Tamoxifen was administered via intraperitoneal (i.p.) in-
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jection to both Map4k4flox/flox (control) and Map4k4flox/flox-
UBC-cre ERT2 (iMap4k4) mice (Fig. 1B). Tamoxifen induced cre
recombinase activity and Map4k4 deletion in iMap4k4 mice, re-
sulting in animals we denote iMap4k4-KO mice. As expected,
Map4k4 mRNA and protein expression was significantly reduced
in all of the tissues collected from iMap4k4-KO mice 18 weeks
post-tamoxifen treatment (Fig. 1C and D). Furthermore, both
control and iMap4k4-KO mice continued to develop normally
after tamoxifen treatment and did not display any obvious motor
or behavioral defects. These results indicate that Map4k4 is not
required for adult mouse viability and that this inducible Map4k4
deletion mouse model can be used to address the metabolic func-
tions of Map4k4 in obese animals.
To assess the role of Map4k4 in metabolic disease, animals
were challenged with a lard-based high (60%)-fat diet (HFD).
Animals with systemic Map4k4 deletion did not display body
weight or adiposity differences from the littermate controls
(Map4k4flox/flox mice treated with tamoxifen) (Fig. 1E and F).
Consistent with this observation, control and iMap4k4-KO mice
consumed similar quantities of food (Fig. 1G). Furthermore, al-
though no gross histological changes were observed in metabolic
tissues (Fig. 1H), the visceral adipose tissue (VAT) displayed a
slight reduction in macrophage content as assessed by histology
(Fig. 1H), RT-qPCR (Fig. 2A), and flow cytometry (Fig. 2B to E).
Interestingly, despite similar adiposity results, HFD-fed
iMap4k4-KO animals showed enhanced whole-body insulin re-
sponsiveness as assessed by an insulin tolerance test (ITT) (Fig.
3A). Strikingly, the ITT curves of HFD-fed iMap4k4-KO mice
overlapped those of age-matched lean animals (Fig. 3A), suggest-
ing that whole-body Map4k4 deficiency in obese animals im-
proves peripheral insulin sensitivity to levels similar to those ob-
served in lean controls.We also found that iMap4k4-KOmice had
a significant (20%) reduction in fasting glucose levels (Fig. 3B), as
well as lower circulating insulin levels (Fig. 3C), consistent with
increased insulin responsiveness in vivo. However, no changes in
the results of the glucose tolerance test (GTT) were detected
(Fig. 3B).
As an additional assessment of insulin sensitivity on a cellular
level, we measured insulin signaling in adipose, liver, and muscle
tissue following a bolus insulin injection into HFD-fed animals.
Consistent with enhanced whole-body insulin responsiveness,
FIG 1 Characterization of tamoxifen-inducible whole-body iMap4k4-KO
mice. (A) Schematic of alleles and transgenes used to inactivate Map4k4 sys-
temically in adult tissues using tamoxifen. (B) Schematic of experimental de-
sign. Both control (Map4k4flox/flox) and iMap4k4 (Map4k4flox/flox-UBC-cre
ERT2)micewere injectedwith tamoxifen as detailed inMaterials andMethods
to produce iMap4k4-KO mice. (C and D) Analysis was performed 18 weeks
after first tamoxifen injection. (C) Map4k4 mRNA expression (n  6 to 10).
(D) Representative Map4k4 protein immunoblot with tubulin as the loading
control (Ctl) (n  6). (E to H) Control and iMap4k4-KO mice were fed a
normal chow diet (ND) or a high-fat diet (HFD) for 16 weeks starting 2 weeks
after the 1st tamoxifen injection. (E) Body weight (n  16). (F) Fat and lean
mass analysis in HFD-fed mice (n  4 to 6). (G) Food intake in mice fed an
HFD (n 4 to 6). (H) Representative liver, skeletal muscle, and adipose tissue
histology of HFD-fed mice stained for H&E (n 6). Arrows indicate crown-
like-structures, and asterisks sites indicate of inflammation. Data represent
means SEM (*, P 0.01; **, P 0.001; ***, P 0.0001).
FIG 2 Systemic Map4k4 deletion reduces adipose tissue inflammation with-
out changing adiposity. Animals were fed an HFD for 16 weeks, and visceral
adipose tissue was isolated. (A) Relative levels of mRNA expression of various
inflammatory genes as indicated (n 7). (B) The VAT stromal vascular frac-
tion was isolated and fluorescence-activated cell sorter (FACS) analysis per-
formed. Representative FACS scatter plots for control mice and iMap4k4-KO
mice are shown. The upper plots show F4/80- and CD11b-positive cells, while
the lower plots show CD11b- and CD11c-positive cells (n  10 to 13). (C)
Number of macrophages (F4/80-positive cells) per milligram of VAT (n 10
to 13). (D) Percentage of CD11c-positive cells (n  10 to 13). (E) CD11c-
positive cells per milligram of VAT (n  10 to 13). Data represent average
means SEM (*, P 0.05; **, P 0.005).
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iMap4k4-KO mice showed significant improvements in insulin-
induced AKT phosphorylation (at Ser473 and Thr308) in the liver
and in the VAT (Fig. 3D and E). These data indicate that
iMap4k4-KOmice are protected from obesity-induced insulin re-
sistance at least in part by enhancement of insulin signaling to
AKT in adipose tissue and liver. Because obesity leads to glucose
intolerance and insulin resistance in various organs, including ad-
ipose tissue, liver, and muscle, we aimed to identify the contribu-
tion of Map4k4 in each of these tissues to whole-body glucose
homeostasis and insulin sensitivity.
AdiposeMap4k4 does not influence whole-body glucose ho-
meostasis. Obesity-induced adipose tissue dysfunction—in-
cluding adipose tissue inflammation, altered adipokine secre-
tion, and reduced lipid-buffering capacity—contributes to
the development of whole-body insulin resistance (15–19).
Since Map4k4 expression is elevated in obese human adipose
tissue (20) and studies performed in vitro suggest Map4k4 is a
negative regulator of insulin action (5, 8), we aimed to specif-
ically ablate Map4k4 expression in adipocytes by crossing
Map4k4flox/flox mice to adiponectin-cre transgenic mice (Fig. 4A).
As controls, Map4k4flox/flox littermates that do not express cre re-
combinase were used. The resulting adipose-specific knockout
(Ad-Map4k4-KO) mice displayed disrupted Map4k4 expression
in the adipocyte fractions of all the adipose tissue depots examined
(visceral, subcutaneous, and brown adipose) but not in the spleen
or the heart (Fig. 4B and C). Isolated adipocytes were used to
confirm Map4k4 depletion in adipocytes, as the adipose tissue is
composed of various cell types, including immune cells, preadi-
pocytes, and vascular cells. To test whether the enhanced insulin
sensitivity previously observed in obese iMap4k4-KO mice was
mediated by the actions ofMap4k4 in adipose tissue, animals were
challenged with an HFD for 16 weeks. Ad-Map4k4-KO animals
developed normally and gained weight and fat mass in a manner
similar to that seen with control littermates fed an ND or an HFD
(Fig. 4D to F). To assess whether Ad-Map4k4-KOmice displayed
altered FA release, which might impact glucose metabolism,
nonesterified fatty acid (NEFA) levels were measured under basal
conditions and after 3-adrenergic stimulation (i.p. injection of
FIG 3 SystemicMap4k4 deletion ameliorates obesity-inducedmetabolic dysfunction and enhances insulin signaling in adipose and liver. (A and B) Control and
iMap4k4-KOmicewere fed anNDor anHFD for 16weeks. (A) Percentage of basal glucose remaining during insulin tolerance test (ITT) (n 7 to 17). (B) Blood
glucose levels during glucose tolerance test (GTT) (n 10 to 17). (C) Fasting insulin levels in HFD-fedmice (n 13). (D) Representative protein immunoblots
of AKT signaling (total, thr308 [308], and ser473 [473]) in liver, adipose tissue, and skeletal muscle 15 min after PBS or insulin injection in HFD-fed animals as
described inMaterials andMethods. (E) Densitometry analyses of the data from the experiments described for panel D (n 6 to 10). Results are means SEM
(*, P 0.05; **, P 0.005; ***, P 0.0005).
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CL 316,243). As expected, NEFA levels were increased following
CL 316,243 injection; however, control and Ad-Map4k4-KOmice
displayed comparable plasmaNEFA levels (Fig. 4G).Metabolic func-
tionsofcontrol andAd-Map4k4-KOmice fedNDorHFDasassessed
by glucose tolerance (GTT) and insulin sensitivity (ITT) were also
similar (Fig. 4Hand I).Consistentwith the lackofmetabolic changes,
control and Ad-Map4k4-KO mice displayed similar fasting insulin
levels (Fig. 4J). Furthermore, results of analysis of inflammation in
both subcutaneousandvisceral adipose tissueas assessedbyhistology
(Fig. 4K) and RT-qPCR (Fig. 4L and M) were also similar between
groups. Overall, these results indicate that loss of Map4k4 in adi-
pocytes does not alter the adipose functions tested or whole-body
glucose metabolism and suggest that the improved adipose insulin
sensitivity observed in iMap4k4-KOmice is not mediated by the ac-
tions ofMap4k4 in the adipose tissues.
Hepatocyte-specificMap4k4 deletion does not improvemet-
abolic parameters in lean or obese mice. In the fed state, insulin
FIG 5 Hepatic Map4k4 does not contribute to systemic glucose tolerance or
insulin responsiveness. (A) Schematic of alleles and transgenes used to inacti-
vate Map4k4 using albumin-cre transgene. (B) Relative levels of Map4k4
mRNA expression in liver, skeletal muscle, and adipose tissue (n  7 to 14).
(C) Relative levels of Map4k4 mRNA expression in isolated hepatocytes (n
3). (D to M) Mice were fed an ND or an HFD for 16 weeks. (D) Body weight
(n 6 to 13). (E) Liver weight (n 6 to 17). (F) Fasting insulin levels (n 4
to 15). (G)NEFA levels of HFD-fedmice (n 4 to 15). (H) GTT (n 8 to 16).
(I) ITT (n  8 to 16). (J) Blood glucose levels during pyruvate tolerance test
(PTT) (n 7 to 16). (K) Livers were isolated and RT-qPCR performed on the
indicated genes of HFD-fed animals (n  5 to 7). (L) Representative liver
histology of HFD-fed mice. Slides were stained with H&E (n 10). (M) Liver
triglyceride (TG) extraction from HFD-fed mice (n  5 to 11). Results are
means SEM (*, P 0.01; ***, P 0.0001).
FIG 4 Adipose-specific Map4k4 deletion in mice does not alter systemic glu-
cose tolerance or insulin responsiveness. (A) Schematic of alleles and trans-
genes used to inactivate Map4k4 in the adipose using adiponectin-cre trans-
gene. (B) Relative levels of Map4k4 mRNA expression in adipose tissues
(visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT], and brown
adipose tissue [BAT]), spleen, and heart (n 4). (C) Relative levels ofMap4k4
mRNA expression in isolated adipocytes fromVAT, SAT, and BAT (n 3). (D
to M) Control and Ad-Map4k4-KO mice were fed an ND or an HFD for 16
weeks. (D) Body weight (n 8 to 14). (E) SATmass relative to body weight (n
 5). (F) VAT mass relative to body weight (n  5). (G) NEFA levels in
HFD-fed mice before and after 1 h CL 316,243 i.p. injection (n 5). (H) GTT
(n 10 to 15). (I) ITT (n 10 to 15). (J) Fasting insulin levels (n 5 to 6). (K)
Representative histology of VAT and SAT in HFD-fed mice. Slides were
stained with H&E (n 10). Arrows indicate crown-like-structures, and aster-
isks indicate sites of inflammation. (L andM) Relative mRNA levels of various
inflammatory genes assessed inVAT (L) (n 6 to 8) and SAT (M) (n 6 to 8).
Results are means SEM (*, P 0.05; ***, P 0.0001).
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suppresses glycogenolysis and gluconeogenesis while stimulating
lipid synthesis in the liver, whereas, under conditions of obesity-
induced insulin resistance, insulin fails to suppress hepatic glucose
production, thereby contributing to elevated blood glucose levels
(21). To assess whether hepatic Map4k4 could account
for the improved insulin sensitivity observed in the HFD-fed
iMap4k4-KO mice, Map4k4flox/flox animals were crossed to mice
expressing a cre transgene driven by the hepatocyte-specific albu-
min promoter (Fig. 5A). Map4k4flox/flox littermates that do not
express cre recombinasewere used as controls.We confirmed spe-
cific deletion ofMap4k4 in hepatocytes and not skeletal muscle or
adipose tissue in Map4k4flox/flox-Alb-cre (Alb-Map4k4-KO) mice
(Fig. 5B and C). Since the liver consists of several cell types, in-
cluding Kupffer cells, we isolated hepatocytes to confirm hepato-
cyte-specific deletion of Map4k4 (Fig. 5B and C). To assess
whether hepatic Map4k4 contributed to whole-body glucose me-
tabolism, control and Alb-Map4k4-KO mice were challenged
with an HFD for 16 weeks. Control littermates and Alb-
Map4k4-KO animals gained weight at similar levels upon high-fat
feeding (Fig. 5D and E), and fasting insulin and NEFA levels were
unchanged between groups (Fig. 5F and G). Furthermore, no al-
terations in fasting glucose levels or pyruvate tolerance test (PTT),
GTT, or ITT results were observed among control and Alb-
Map4k4-KO animals on an ND or an HFD (Fig. 5H to K). Al-
though liver histology of Alb-Map4k4-KO mice revealed a slight
increase in hepatic lipid accumulation compared to controls (Fig.
5L), this modest increase was not statistically significant as as-
sessed by hepatic triglyceride content (Fig. 5M). These results in-
dicate that hepatic Map4k4 depletion does not contribute to the
reduced basal glucose levels or improved insulin sensitivity ob-
served upon inducible whole-body Map4k4 deficiency.
Map4k4 deletion in Myf5-positive cells results in improved
metabolic parameters. Skeletal muscle plays a major role in reg-
ulating whole-body glucose metabolism and is responsible for the
largest fraction of insulin-mediated glucose uptake from the
blood. To determine whether Map4k4 in skeletal muscle affects
whole-body metabolism, we crossed Map4k4flox/flox animals to
mice that express cre recombinase under the control of the Myf5
promoter (Fig. 6A). Myf5-cre was used to delete Map4k4 in mus-
cle precursors because previous reports from our laboratory dem-
onstrated thatMap4k4 plays a key role during early stages of mus-
cle differentiation in C2C12 cells (22). As controls, we used
Map4k4flox/flox littermates, which do not express cre recombinase.
As expected, Map4k4 expression was diminished in several of the
skeletal muscle tissues collected (i.e., trapezius, triceps, and so-
leus) aswell as in brown adipose tissue (BAT), asMyf5 is expressed
in muscle and BAT precursors (Fig. 6B) (23–25). Consistent with
previous reports showing a low (5% to 10%) prevalence of Myf5-
precursor-derived adipocytes in the visceral adipose tissue (VAT),
the relative levels Map4k4 mRNA expression were not altered in
whole VAT (Fig. 6B) (23–25). Isolated adipocytes from VAT dis-
played lower Map4k4 expression levels; however, this decrease
was not due to Map4k4 deletion as assessed by genomic analysis
but likely reflects transcriptional downregulation of Map4k4 ex-
pression in these cells (data not shown).When challenged with an
HFD, both control andMap4k4flox/flox-Myf5-cre (Myf5-Map4k4-
KO)mice gainedweight, although theMyf5-Map4k4-KO animals
tended to be smaller (Fig. 6C). Whole-body lean and fat mass
analysis, however, did not reveal any statistically significant differ-
ences between control and Myf5-Map4k4-KO mice as measured
by 1H-MRS (Fig. 6D) or individual tissue weights (Fig. 6E and F).
Furthermore, measurements of energy metabolism, including
food intake (Fig. 6G), oxygen consumption (Fig. 6H), carbon di-
oxide production (Fig. 6I), energy expenditure (Fig. 6J), and phys-
ical activity levels (Fig. 6K), were not statistically different between
groups. Fasting insulin and NEFA levels were also unchanged in
HFD-fedMyf5-Map4k4-KOmice compared to control mice (Fig.
6L andM). Strikingly, however, despite similar adiposities, HFD-
fed Myf5-Map4k4-KO animals displayed decreased fasting glu-
cose levels and improved glucose clearance during aGTT, suggest-
ing that Myf5-Map4k4-KOmice were more glucose tolerant than
controls (Fig. 6N). We then performed an ITT, and, consistent
with enhanced glucose tolerance, Myf5-Map4k4-KO mice were
significantly more insulin sensitive than controls (Fig. 6O and P).
These results suggest that Map4k4 deletion in Myf5-positive cells
recapitulates in large part themetabolic benefits observed inHFD-
fed iMap4k4-KO mice and demonstrate that Map4k4 in Myf5-
positive cells promotes obesity-induced metabolic dysfunction.
To further assess peripheral insulin sensitivity in the Myf5-
Map4k4-KO mice, HFD-fed control and Myf5-Map4k4-KO ani-
mals were injected with PBS or insulin followed by collection of
liver, adipose tissue, and skeletal muscle samples. Myf5-
Map4k4-KOmice displayed a modest increase in AKT phosphor-
ylation in response to insulin in the soleus muscle, a tissue with
near-complete Map4k4 ablation, and no changes in AKT phos-
phorylation in the liver (Fig. 7A and B). Surprisingly, Myf5-
Map4k4-KOmice displayed a striking enhancement ofAKTphos-
phorylation in the VAT (Fig. 7A and B), a tissue that expressed
normal Map4k4 levels in these mice (Fig. 6B). No gross morpho-
logical changes were observed in either skeletal muscle or VAT
that could explain improved whole-body insulin action (Fig. 7C),
and the two groups of mice displayed similar adipose tissue in-
flammation profiles as assessed by histology and RT-qPCR of in-
flammatory markers (Fig. 7C and D). To assess whether muscle-
secreted factors (myokines) were altered in Myf5-Map4k4-KO
mice, leading to improved insulin signaling in VAT, we measured
the relative levels of gene expression of known myokines in the
skeletal muscle (soleus) (Fig. 7E) as well as total circulating levels
of fibroblast growth factor 21 (FGF21) (Fig. 7F), interleukin-6
(IL-6) (Fig. 7G), and irisin (Fig. 7H) and found no differences
between control andMyf5-Map4k4-KOmice. These results dem-
onstrate that Map4k4 deletion in Myf5-positive tissues protects
mice from obesity-induced glucose intolerance and insulin resis-
tance and that this protection may be mediated in part via an
indirect effect on the visceral adipose tissue.
Taken together, the data obtained from our four Map4k4
knockout mouse models presented here suggest that the meta-
bolic improvements observed in iMap4k4-KO mice may be due
primarily to the actions of Map4k4 in cells derived from Myf5-
positive skeletal muscle cells and not to the actions of Map4k4
expressed in adipose cells or hepatocytes. Since Ad-Map4k4-KO
animals (which also induce Map4k4 deletion in BAT) do not dis-
play any metabolic changes, skeletal muscle rather than BAT is
more likely responsible for themetabolic improvements observed
in Myf5-Map4k4-KO mice. Furthermore, these data suggest that
there is physiological cross talk between Myf5-positive cells and
the visceral adipose tissue that contributes to obesity-induced in-
sulin resistance and that Map4k4 may be an important key regu-
lator of this cross talk.
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FIG6 Map4k4 deletion inMyf5-positive tissues improves glucose tolerance and insulin responsiveness. (A) Schematic of alleles and transgenes used to inactivate
Map4k4 usingMyf5-cre knock-in allele. (B) Relative levels ofMap4k4mRNA expression in variousmuscles, adipose tissues, and liver (n 5). Quad, quadriceps;
EDL, extensor digitorum longus; TA, tibialis anterior. (C toM)Mice were fed anNDor anHFD for 8weeks. (C) Bodyweight (n 7 to 18). (D) Fat and leanmass
analysis using 1H-MRS (n 5). (E) Adipose tissues relative to body weight in ND-fedmice. Data represent visceral adipose tissue (VAT), inguinal subcutaneous
adipose tissue (iWAT), axial subcutaneous adipose tissue (aWAT), perirenal adipose tissue (pWAT), and brown adipose tissue (BAT) (n 8). (F)Muscle weight
relative to body weight in ND-fed mice (n 8). (G to M) Mice were fed an HFD for 8 weeks. (G) Food intake (n 5). (H) Oxygen consumption rate (n 5).
(I) Carbondioxide production rate (n 5). (J) Energy expenditure rate (n 5). (K)Total activity levels (n 5). (L) Fasting insulin levels (n 6 to 8). (M) Fasting
NEFA levels (n 5). (N) GTT (n 7 to 17). (O) ITT of ND-fed animals (n 11 to 19). (P) ITT of HFD-fed animals (n 7 to 13). Results are means SEM
(*, P 0.05; **, P 0.005).
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The results presented here demonstrate a role for Map4k4 in pro-
moting obesity-induced insulin resistance, suggesting Map4k4 as
a novel potential therapeutic target for the treatment of T2D. In-
duced systemic Map4k4 deficiency improves metabolic health in
obese mice by lowering fasting glucose levels and improving insu-
lin sensitivity (Fig. 3). While this beneficial effect of systemic
Map4k4 deletion in mature mice is associated with enhanced in-
sulin signaling to AKT in adipose tissue and liver (Fig. 3), condi-
tional-KO mice with selective Map4k4 deletion either in adipose
tissue depots (Fig. 4) or in liver (Fig. 5) display no overt metabolic
phenotypes. Rather, Map4k4 deficiency inMyf5-positive cells, in-
cluding all skeletal muscles, largely recapitulates the effects ob-
served in inducible whole-bodyMap4k4-ablatedmice, improving
metabolic functions in the obese state (Fig. 6). Surprisingly,
Map4k4 deletion in Myf5-positive cells causes enhancement of
insulin signaling to AKT in VAT (Fig. 7), a tissue that is nearly
devoid of Myf5 expression (26), indicating the presence of inter-
esting intertissue signaling between Map4k4-deficient Myf5-pos-
itive cells and white adipocytes.
Employing iMap4k4-KOmice, we bypassed the embryonic le-
thality observed in constitutiveMap4k4-null mice (10) and found
that Map4k4 is not essential for adult viability. Indeed, the
iMap4k4-KO mice whose results are presented here did not dis-
play any obvious behavioral defects and continued to gain weight
throughout the study (Fig. 1E and F). Furthermore, despite simi-
lar adiposity results, inducible systemic Map4k4 deletion en-
hanced whole-body insulin action via improved adipose and liver
insulin sensitivity (Fig. 3A, D, and E). Interestingly, iMap4k4-KO
mice displayed slightly reduced adipose tissue inflammation
(Fig. 2), which is consistent with previous data showing that
Map4k4 silencing in macrophages in vivo dampens inflammation
FIG 7 Map4k4 deletion inMyf-5-positive tissues improves insulin signaling in visceral adipose tissue. (A to D) Animals were fed an ND or an HFD for 8 weeks.
(A) Representative protein immunoblot of AKT signaling in liver, skeletal muscle, and VAT in response to a bolus insulin injection (1 U/kg) as described in
Materials andMethods. (B)Densitometry analysis of the data from the experiment described for panel A (n 6 or 7). (C) Representative skeletalmuscle (soleus)
and VAT histology of HFD-fed control andMyf5-Map4k4-KOmice. Slides were stained with H&E (n 10). (D) VATwas isolated and RT-qPCR performed on
the indicated genes of HFD-fed animals (n 6 to 12). (E to H) Animals were fed an HFD for 8 weeks. (E) Relative levels of gene expression in skeletal muscle
(soleus). Data represent circulating levels of FGF21 (F), IL-6 (G), and irisin (H). Results are means SEM (*, P 0.05; **, P 0.005; ***, P 0.0001).
Map4k4 Promotes Obesity-Induced Metabolic Dysfunction
July 2015 Volume 35 Number 13 mcb.asm.org 2363Molecular and Cellular Biology
 o
n











in lean mice (27). Future studies using conditional Map4k4 dele-
tion in macrophages will be required to assess the role of Map4k4
in immune cells in metabolic disease.
Previous reports have shown that enhanced peripheral insulin
sensitivity can be associated with lowered insulin levels, as less
insulin is needed to clear glucose from the circulation (28–30).
Consistent with these reports, iMap4k4-KO mice displayed re-
duced insulin levels compared to controls (Fig. 3C). However,
although the obese iMap4k4-KOmice weremore insulin sensitive
and displayed lower fasting glucose levels than the controls (Fig.
3B), no changes in glucose clearance were detected (Fig. 3B). We
hypothesize that the reduced insulin levels in the iMap4k4-KO
mice are at least in part secondary to enhanced peripheral insulin
sensitivity. However, lower insulin levels could also explain im-
provements in whole-body insulin action with minimal changes
in glucose tolerance. Thus, these results are not inconsistent with
the notion that Map4k4 plays a role in pancreatic -cell function,
potentially promoting insulin secretion in the obese state. Addi-
tional studies will be required to address a possible role for
Map4k4 in pancreatic -cell function in vivo.
Although we initially identifiedMap4k4 in a screen for regula-
tors of adipocyte function and found significant effects ofMap4k4
on glucose uptake and lipogenesis in cultured adipocytes (5, 8), we
have not found significant metabolic effects in mice with adipose-
specific Map4k4 ablation. One possibility is that the influence of
Map4k4 is diminished in a more complex in vivo environment, in
which these functions are regulated bymultiple intertissue signals,
including neuronal and endocrine signals that are absent in cul-
tured cell models. Another possibility is that activity of related
Ste20 kinases such as Traf2 and Nck interacting kinase (Tnik) and
Misshapen-like kinase 1 (Mink1) compensates for the loss of
Map4k4 in the adipose tissue in vivo.
UsingMyf5-cre mice to deplete Map4k4 in skeletal muscle, we
found that despite the equal levels of adiposity (Fig. 6C to E),
Myf5-Map4k4-KO mice were resistant to obesity-induced meta-
bolic dysfunction (Fig. 6N and P). Because previous work in our
laboratory suggested that Map4k4 is highly expressed in satellite
cells and may play a role during early stages of muscle differenti-
ation (22), we selected a cre recombinase driven by a promoter
that is expressed during this time frame (31–33). However, skele-
tal muscle weights (Fig. 6F) and histology results (Fig. 7C) ap-
peared normal inMyf5-Map4k4-KOmice, suggesting no changes
in muscle development. Although recent studies indicate that
Myf5 is also expressed in certain adipose tissue depots (23–25), we
hypothesize that Myf5-expressing myocytes and not brown adi-
pose cells mediate the metabolic effects observed in Myf5-
Map4k4-KO mice, as Ad-Map4k4-KO animals, which also delete
in the BAT, do not display any improvements in metabolic func-
tion (Fig. 4). Interestingly, although Myf5-Map4k4-KO mice did
not display any changes in Map4k4 expression in whole VAT,
these mice displayed lower Map4k4 expression in isolated adi-
pocytes from VAT; however, this decrease in Map4k4 expression
was not mediated by Map4k4 deletion as indicated by analysis of
genomic DNA (data not shown). Furthermore, we hypothesize
that this decrease in Map4k4 expression in isolated adipocytes is
not responsible for the metabolic changes observed in Myf5-
Map4k4-KO mice, as adipose-specific Map4k4 deletion did not
alter metabolic parameters (Fig. 4).
Map4k4 deletion in the Myf5-positive tissues largely reca-
pitulates the improved metabolic effects observed upon sys-
temic Map4k4 ablation, protecting mice from obesity-induced
metabolic dysfunction. Although both iMap4k4-KO andMyf5-
Map4k4-KO mice display enhanced whole-body insulin action
and reduced fasting glucose levels (Fig. 3 and 6), glucose clear-
ance was not altered in iMap4k4-KO mice (Fig. 3B). Since
iMap4k4-KOmice deplete Map4k4 systemically, this discrepancy
between models may be due to a potential role of Map4k4 in the
pancreas which is observed only in iMap4k4-KOmice. Consistent
with this hypothesis, iMap4k4-KO mice display reduced fasting
insulin levels (Fig. 3C), whereas Myf5-Map4k4-KO mice do not
(Fig. 6N). Both models, however, displayed improved peripheral
insulin sensitivity in association with enhanced insulin signaling
to AKT in VAT (Fig. 7A); thus, these data are consistent with
previous studies that showed that silencing Map4k4 expression
prevents cytokine-induced insulin resistance (9).
Because Myf5-Map4k4-KO mice displayed improved insulin
sensitivity in the VAT (Fig. 7A and B), a tissue that did not show
Map4k4 deletion (Fig. 6B), Map4k4 ablation in Myf5-positive
cells apparently impacts Myf5-negative tissues. This observation
suggests that Map4k4 could regulate production or activity of an
as-yet-unidentified factor (or factors) that in turn influences adi-
pose tissue insulin sensitivity. Several muscle-derived mediators
have been identified, including FGF21, IL-6, and irisin (34).
FGF21 and IL-6 are mostly secreted from other tissues, including
the liver under fasting conditions (FGF21) and immune cells dur-
ing an inflammatory response (IL-6) (34). We measured the
mRNA expression and circulating levels of these two secreted fac-
tors and found no statistically significant differences between con-
trol and Myf5-Map4k4-KO mice (Fig. 7). Another candidate, iri-
sin, has been reported to increase in level after exercise and to
induce a white-to-brown shift in adipocytes (35), but we have not
observed changes in gene expression or circulating levels of irisin
and we also have not observed any white-to-brown shift in either
VAT or SAT (data not shown). Thus, future studies will aim to
identify the putative circulating factor(s) that improves insulin
sensitivity in Myf5-Map4k4-KO mice.
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